Deferasirox Market Will Surge at 4.50% CAGR to Reach 3230 Million US$ by the End of 2025 QY Research, Inc.
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
View full press release